Locoregional radionuclide cancer therapy (LRCT) using sealed and unsealed radionuclides

Different approaches of LRCT using sealed and unsealed radionuclides are reexamined and contrasted to allow optimal choice to treat human cancers. With the production of devices of smaller particulate sizes and of soluble radiopharmaceuticals of more potency and longer half-life, the distinction of sealed versus unsealed radiopharmaceuticals differs only in the choice of compliance pathways and becomes less important. There are many choices of radiopharmaceuticals for LRCT such as sealed versus unsealed radiopharmaceuticals, those with versus those without tumor affinity, and particulate versus soluble forms. These choices will allow treating human cancer with less toxic and more efficacious applications.